# US 2025/0205334 A1 · Antibody Compositions and Methods of Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0205334 A1
- Document ID: US20250205334A1
- Status: Published application
- Kind: A1
- Application number: 18/812,813
- Filed: 2024-08-22
- Published: 2025-06-26
- Earliest claimed: 2020-12-28
- Assignees: Bristol-Myers Squibb Company; Halozyme, Inc.
- Applicants: Bristol-Myers Squibb Company; Halozyme, Inc.
- Inventors: Masano HUANG; Thomas Arthur HABY; Mehrnaz KHOSSRAVI; Scott Aaron HART; Rao Venkatramana MANTRI; Heather Elizabeth VEZINA; Amit ROY; Bindu Purnima MURTHY; Urvi Ashish ARAS; Kinjal SANGHAVI; Xiaochen ZHAO; Akintunde BELLO
- Web page: https://patentgrep.com/patent/US20250205334A1

## CPC

- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C12Y 302/01035: Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61M 5/14248: {of the skin patch type}
- C07K 2317/21: from primates, e.g. man
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

The disclosure provides pharmaceutical compositions comprising an antibody and at least two antioxidants. In some aspects, pharmaceutical composition is formulated for subcutaneous delivery. In some aspects, the pharmaceutical composition further comprises an endoglycosidase hydrolase enzyme. Other aspects of the present disclosure are directed to methods of subcutaneously delivering the pharmaceutical composition.

## Claims

### Claim at position 1

1-50. (canceled)

### Claim 51

A pharmaceutical composition, comprising:
(i) (a) about 120 mg/mL of nivolumab;
(b) about 20 mM histidine,
(c) about 250 mM sucrose,
(d) about 0.05% w/v polysorbate 80,
(e) about 50 μM pentetic acid,
(f) about 5 mM methionine, and
(g) about 2000 U/mL rHuPH20; or
(ii) (a) about 150 mg/mL of nivolumab,
(b) about 20 mM histidine,
(c) about 250 mM sucrose,
(d) about 0.05% w/v polysorbate 80,
(e) about 50 μM pentetic acid,
(f) about 5 mM methionine, and
(g) about 2000 U/mL rHuPH20.

### Claim at position 3

52-57. (canceled)

### Claim 58 (depends on 51)

The pharmaceutical composition of claim 51, comprising:
(a) about 120 mg/mL nivolumab;
(b) about 20 mM histidine;
(c) about 250 mM sucrose;
(d) about 0.05% w/v polysorbate 80;
(e) about 50 μM pentetic acid;
(f) about 5 mM methionine; and
(g) about 2000 U/mL rHuPH20.

### Claim at position 5

59-61. (canceled)

### Claim 62 (depends on 51)

The pharmaceutical composition of claim 51, comprising a pH of about 5.2 to about 6.8.

### Claim 63

(canceled)

### Claim 64 (depends on 51)

The pharmaceutical composition of claim 51, comprising a pH of about 6.0.

### Claim at position 9

65-74. (canceled)

### Claim 75 (depends on 51)

A vial comprising the pharmaceutical composition of claim 51.

### Claim 76 (depends on 51)

A syringe comprising the pharmaceutical composition of claim 51.

### Claim 77 (depends on 51)

An auto-injector comprising the pharmaceutical composition of claim 51.

### Claim 78 (depends on 51)

A wearable pump comprising the pharmaceutical composition of claim 51.

### Claim 79 (depends on 76)

The syringe of claim 76, further comprising a plunger.

### Claim 80 (depends on 51)

A method of treating a disease or disorder in a subject in need thereof comprising administering to the subject a pharmaceutically effective amount of the pharmaceutical composition of claim 51.

### Claim 81 (depends on 80)

The method of claim 80, wherein the pharmaceutical composition is administered subcutaneously.

### Claim at position 17

82-167. (canceled)

### Claim 168 (depends on 51)

The pharmaceutical composition of claim 51, wherein the rHuPH20 comprises the amino acid sequence set forth in SEQ ID NO: 5.

### Claim 169 (depends on 58)

The pharmaceutical composition of claim 58, wherein the rHuPH20 comprises the amino acid sequence set forth in SEQ ID NO: 5.

### Claim 170 (depends on 51)

The pharmaceutical composition of claim 51, wherein the total amount of nivolumab is 600 mg.

### Claim 171 (depends on 51)

The pharmaceutical composition of claim 51, wherein the total amount of nivolumab is 900 mg.

### Claim 172 (depends on 51)

The pharmaceutical composition of claim 51, wherein the total amount of nivolumab is 1200 mg.

### Claim 173 (depends on 58)

The pharmaceutical composition of claim 58, wherein the total amount of nivolumab is 600 mg.

### Claim 174 (depends on 58)

The pharmaceutical composition of claim 58, wherein the total amount of nivolumab is 900 mg.

### Claim 175 (depends on 58)

The pharmaceutical composition of claim 58, wherein the total amount of nivolumab is 1200 mg.

### Claim 176 (depends on 169)

The pharmaceutical composition of claim 169, wherein the total amount of nivolumab is 600 mg.

### Claim 177 (depends on 169)

The pharmaceutical composition of claim 169, wherein the total amount of nivolumab is 900 mg.

### Claim 178 (depends on 169)

The pharmaceutical composition of claim 169, wherein the total amount of nivolumab is 1200 mg.

### Claim 179 (depends on 58)

A method of treating a disease or disorder in a subject in need thereof comprising administering to the subject a pharmaceutically effective amount of the pharmaceutical composition of claim 58.

### Claim 180 (depends on 173)

A method of treating a disease or disorder in a subject in need thereof comprising administering to the subject a pharmaceutically effective amount of the pharmaceutical composition of claim 173.

### Claim 181 (depends on 174)

A method of treating a disease or disorder in a subject in need thereof comprising administering to the subject a pharmaceutically effective amount of the pharmaceutical composition of claim 174.

### Claim 182 (depends on 175)

A method of treating a disease or disorder in a subject in need thereof comprising administering to the subject a pharmaceutically effective amount of the pharmaceutical composition of claim 175.
